Third Rock Ventures Launches Fulcrum Therapeutics with $55 Million Series A Investment

Third Rock Ventures, LLC today announced the launch of Fulcrum Therapeutics, a company focused on unlocking gene control mechanisms to develop small molecule therapies. Fulcrum will discover and develop small molecules that modulate the on/off control mechanisms that regulate genes. Read More